Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.

Pediatric clinics of North America - 1 Oct 2012

Wagner Jonathan, Leeder J Steven

Abstract excerpt

The dose-exposure-response relationship for drugs may differ in pediatric patients compared with adults. Many clinical studies have established drug dose-exposure relationships across the pediatric age spectrum; however, genetic variation was seldom included. This article applies a systematic approach to determine the relative contribution of development and genetic variation on drug disposition and response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Cholesterol, LDL
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyslipidemias

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Pediatrics

Share to Pharmacogenetics

Share to Research Design

Source

Open in PubMed Open full text

Identifiers

PMID: 23036242
DOI: 10.1016/j.pcl.2012.07.008
PMCID: PMC5847265

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.PMID 23036242Read ↗

Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.Semantic proximity Read ↗

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.Semantic proximity Read ↗

Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy.Semantic proximity Read ↗

Individualizing the use of medications in children: making Goldilocks happy.Semantic proximity Read ↗

Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults.Semantic proximity Read ↗

Gene-Based Dose Optimization in ChildrenSemantic proximity Read ↗

Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.Semantic proximity Read ↗

Characterizing variability in warfarin dose requirements in children using modelling and simulation.Semantic proximity Read ↗

Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology.Semantic proximity Read ↗

Identifying genomic and developmental causes of adverse drug reactions in children.Semantic proximity Read ↗

Ontogeny of Phase I Metabolism of DrugsSemantic proximity Read ↗

Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.